Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication

Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Altho...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2022-03, Vol.14 (3), p.612
Main Authors: Tripp, Ralph A, Martin, David E
Format: Article
Language:English
Subjects:
antiviral
Antiviral activity
Antiviral agents
Coronaviruses
COVID-19 - drug therapy
Drug Repositioning
Humans
Influenza
Influenza A
influenza virus
Orthomyxoviridae
Pandemics
Probenecid - pharmacology
Replication
repurposed
Respiratory syncytial virus
Respiratory Syncytial Virus, Human
respiratory virus
Review
RSV
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Viral replication and transmissibility are the principal causes of endemic and pandemic disease threats. There remains a need for broad-spectrum antiviral agents. The most common respiratory viruses are endemic agents such as coronaviruses, respiratory syncytial viruses, and influenza viruses. Although vaccines are available for SARS-CoV-2 and some influenza viruses, there is a paucity of effective antiviral drugs, while for RSV there is no vaccine available, and therapeutic treatments are very limited. We have previously shown that probenecid is safe and effective in limiting influenza A virus replication and SARS-CoV-2 replication, along with strong evidence showing inhibition of RSV replication in vitro and in vivo. This review article will describe the antiviral activity profile of probenecid against these three viruses.
ISSN:1999-4915
1999-4915
DOI:10.3390/v14030612